(Q24245173)

title

Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

12 May 2020

0 references

0 references

4

Edward Gregg

E

Gregg

1 reference

19 October 2023

S L Norris

1

S L

Norris

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

12 May 2020

19 October 2023

X Zhang

2

X

Zhang

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

12 May 2020

19 October 2023

A Avenell

3

A

Avenell

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

12 May 2020

19 October 2023

C H Schmid

5

C H

Schmid

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

12 May 2020

19 October 2023

J Lau

6

J

Lau

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

12 May 2020

Cochrane Database of Systematic Reviews

19 October 2023

language of work or name

1 reference

24 January 2005

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

12 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

12 May 2020

page(s)

CD004096

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

12 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

A Study of Fluoxetine in Obese Elderly Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Fluoxetine in the treatment of obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Fluoxetine's effect on weight loss in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Effects of sibutramine in non-dieting obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Fluoxetine: a randomized clinical trial in the maintenance of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Treatment of patients with non-insulin-dependent diabetes mellitus: diabetic control and insulin secretion and action after different treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Clinical and basic aspects of an anorexlant, mazindol, as an antlobeslty agent in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Clinical studies with mazindol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Cimetidine suspension as adjuvant to energy restricted diet in treating obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Effects of sibutramine on resting metabolic rate and weight loss in overweight women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Effect of cimetidine suspension on appetite and weight in overweight subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

A Multicentre Study Comparing Mazindol and Placebo in Obese Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Obesity and disease management: effects of weight loss on comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Medical evaluation and treatment of the obese patient with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Promoting weight loss in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Systematic reviews and lifelong diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Prevalence and Trends in Obesity Among US Adults, 1999-2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Long-term weight loss: the effect of pharmacologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Obesity medications and the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Guidelines for meta-analyses evaluating diagnostic tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Selective attrition causes overestimates of treatment effects in studies of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

The prevention and treatment of obesity. Application to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Diabetes trends in the U.S.: 1990-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Combining behavioral and pharmacological treatments for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Medical hazards of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Weight loss and mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Antiobesity pharmacotherapy in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Misleading funnel plot for detection of bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Publication bias in meta-analysis: its causes and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Behavioral treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Intentional weight loss and mortality among overweight individuals with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Behavioral treatment of severe obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

Treatment with orlistat reduces cardiovascular risk in obese patients

21 January 2018

1 reference

12 December 2020

WHO Expert Committee on Diabetes Mellitus: second report

1 reference

12 December 2020

Publication bias in obesity treatment trials?

1 reference

12 December 2020

Current and potential drugs for treatment of obesity

1 reference

12 December 2020

1 reference

12 December 2020

Therapy of obesity with "Redukal"

1 reference

12 December 2020

A comparative trial of different regimens of fenfluramine and phentermine in obesity

1 reference

12 December 2020

Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men.

1 reference

12 December 2020

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

12 December 2020

Ephedrine as an anorectic: the story of the 'Elsinore pill'

1 reference

12 December 2020

Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management.

1 reference

12 December 2020

A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity

1 reference

12 December 2020

Double-blind clinical evaluation of mazindol (42-548) in obese diabetics

1 reference

12 December 2020

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial

1 reference

12 December 2020

The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial

1 reference

12 December 2020

A double-blind randomized placebo-controlled trial of sibutramine

1 reference

12 December 2020

Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group

1 reference

12 December 2020

Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity

1 reference

12 December 2020

Fluoxetine therapy in obese diabetic and glucose intolerant patients

1 reference

12 December 2020

Enhanced thermogenic responsiveness during chronic ephedrine treatment in man.

1 reference

12 December 2020

Changes in weight during a 1-year trial of fluoxetine

1 reference

12 December 2020

Phenmetrazine hydrochloride and methylcellulose in the treatment of "refractory" obesity

1 reference

12 December 2020

The continuing epidemics of obesity and diabetes in the United States

1 reference

12 December 2020

Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective

1 reference

12 December 2020

A clinical evaluation of tenuate--a new anti-appetite compound

1 reference

12 December 2020

A randomized double-blind clinical trial of fluoxetine in obese diabetics

1 reference

12 December 2020

Weight control in obese diabetics. A comparative trial of Filon and phenmetrazine

1 reference

12 December 2020

The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial

1 reference

12 December 2020

Weight reduction in osteoarthritis using phentermine

1 reference

12 December 2020

Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects

1 reference

12 December 2020

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

1 reference

12 December 2020

Health implications of obesity. National Institutes of Health Consensus Development Conference Statement

1 reference

12 December 2020

A controlled trial of phentermine in obese diabetic patients

1 reference

12 December 2020

[Use of teronak for the treatment of obesity with and without diabetes mellitus]

1 reference

12 December 2020

Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.

1 reference

12 December 2020

A one-year trial to assess the value of orlistat in the management of obesity

1 reference

12 December 2020

Sibutramine reduces food intake in non-dieting women with obesity

1 reference

12 December 2020

Fluoxetine: a randomized clinical trial in the treatment of obesity

1 reference

12 December 2020

A double blind controlled trial of a new anorectic agent AN448

1 reference

12 December 2020

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

1 reference

12 December 2020

Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes

1 reference

12 December 2020

Behavior change, weight loss, and physiological improvements in type II diabetic patients

1 reference

12 December 2020

Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity

1 reference

12 December 2020

Does ephedrine promote weight loss in low-energy-adapted obese women?

1 reference

12 December 2020

Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women

1 reference

12 December 2020

Long-term effects of modest weight loss in type II diabetic patients

1 reference

12 December 2020

Standards of medical care for patients with diabetes mellitus

1 reference

12 December 2020

The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans

1 reference

12 December 2020

[Reduction of obesity and improvement in metabolic parameters by inhibition of intestinal lipases: current results with orlistat]

1 reference

12 December 2020

The impact of pharmacotherapy on weight management in type 2 diabetes

1 reference

12 December 2020

Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial

1 reference

12 December 2020

New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat

1 reference

12 December 2020

Obesity in diabetes. Some considerations on treatment

1 reference

12 December 2020

Mazindol in the treatment of obesity in diabetics (author's transl)

1 reference

12 December 2020

A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters

1 reference

12 December 2020

Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients

1 reference

12 December 2020

Ephedrine: a new treatment for diabetic neuropathic oedema

1 reference

12 December 2020

Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial

1 reference

12 December 2020

Report of the expert committee on the diagnosis and classification of diabetes mellitus

1 reference

12 December 2020

A comparison of sibutramine and dexfenfluramine in the treatment of obesity

1 reference

12 December 2020

Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity

1 reference

12 December 2020

1 reference

12 December 2020

Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collab

1 reference

12 December 2020

Behavior therapy and pharmacotherapy for obesity

1 reference

12 December 2020

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

12 December 2020

Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients

1 reference

12 December 2020

Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.

1 reference

12 December 2020

Trial of a long-acting preparation of diethylpropion in obese diabetics

1 reference

12 December 2020

Comparison of fluoxetine and placebo in the treatment of obesity

1 reference

12 December 2020

Use of diethylpropion in obese diabetic patients

1 reference

12 December 2020

The effect of an anorectic agent (Mazindol) on control of obese diabetics

1 reference

12 December 2020

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

12 December 2020

Mazindol in the treatment of obese diabetic patients

1 reference

12 December 2020

A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity.

1 reference

12 December 2020

Fluoxetine treatment of the obese diabetic

1 reference

12 December 2020

Weight reduction with phenmetrazine and chlorphentermine a double-blind study

1 reference

12 December 2020

Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamine.

1 reference

12 December 2020

Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study

1 reference

12 December 2020

Weight reduction in obese diabetics: a double-blind study of diethylpropionate (author's transl)

1 reference

12 December 2020

Usefulness of mazindol in combined diet therapy consisting of a low-calorie diet and Optifast in severely obese women

1 reference

12 December 2020

EXPERIENCES WITH THE THERAPEUTIC USE OF AN ANOREXIC SUBSTANCE ON DIABETES OF THE OBESE

1 reference

12 December 2020

Yohimbine does not affect fat distribution in men

1 reference

12 December 2020

Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss

1 reference

12 December 2020

Diethylpropion hydrochloride (Tenuate Dospan) in combination with hypotensive agents in the treatment of obesity associated with hypertension.

1 reference

12 December 2020

The Combination of Estimates from Different Experiments

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004096.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD004096.PUB2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

release_xjxet67rpzaalhwjxegdxsv57q

12 May 2020

Fatcat ID

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6718205&resulttype=core&format=json

12 May 2020

1 reference